United States Food & Drug Administration (USFDA) has completed inspection at Wanbury’s Patalganga site, Maharashtra. USFDA Inspection started from June 10, 2024 and completed on June 14, 2024 with zero-483 observations.
This is 6th successful US FDA inspection of Wanbury Patalganga site. The Company is committed for Quality and compliances as per regulatory requirements at both the API manufacturing sites i.e., Patalganga, Maharashtra and Tanuku, Andhra Pradesh, which is also US FDA approved site. The Company exports APIs to more than 70 countries including US, Europe, Latin America.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: